ClinicalTrials.gg
CompletedNCT06825585Updated Feb 13, 2025

Efficacy and Visual Quality of Orthokeratology Lenses With Different Designs

An interventional study of Orthokeratology with 5.0mm back optical zone diameter and Orthokeratology with a 6.2 mm back optical zone diameter in Myopia and Myopia; Refractive Error, sponsored by Xiaoyan Yang. Completed at 1 site in China. Open to participants aged 8 Years to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Xiaoyan Yang · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled Jan 2021, registered Feb 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
8 Years to 13 Years
Sex
All
01

Study summary

Orthokeratology (ortho-k) lens is very effective in slowing down axial elongation in myopic children by 30% to 63% when compared to children wearing single-vision spectacles or contact lenses. More recently, it is reported that the children wearing orthok lens of smaller back optical zone diameter (BOZD) demonstrated a smaller axial elongation when compared to children wearing lens with larger BOZD. We aimed to explored the myopia efficacy and visual quality of ortho-k with different BOZD (5.0mm or 6.2mm).

Read the detailed description

This prospective study aimed to evaluate the efficacy of orthokeratology lenses with different back optical zone diameters (BOZD) in slowing axial elongation. Additionally, visual quality will be assessed through measurements of wavefront aberrations, contrast sensitivity, and subjective visual quality using a validated questionnaire. The study seeks to explore the effectiveness of various Ortho-K lens designs and the potential factors influencing their outcomes.

02

Conditions studied

  • Myopia
  • Myopia; Refractive Error
03

In context

Myopia

1,007 studies on the registry are indexed under Myopia; 210 are open to participants now.

This study's enrollment of 60 is below the median of 80 across 803 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

This is the only study on the registry with Xiaoyan Yang as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 8 and 13 years.
  • Subjective refraction under cycloplegia: spherical power between -4.00 D and
  • 1.00 D, with cylindrical power≤ 1.50 D.
  • Best-corrected visual acuity (BCVA) of ≥ 1.0 based on subjective refraction.
  • Willing to participate in the clinical trial and provide signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • One eye met the inclusion criteria
  • Patients with systemic diseases causing immunocompromised or affecting orthokeratology
  • There are other eye diseases that affect orthokeratology lens wearing, such as dacryocystitis, blepharitis, various inflammation, glaucoma, etc
  • Abnormal cornea
  • Previous corneal surgery or corneal trauma history
  • Active keratitis (e.g., corneal infection)
  • Patients with best corrected distance visual acuity of less than 5.0
  • Patients with corneal flat curvature lower than 39.00D, or higher than 48.00D
  • Patients with refractive instability
  • Patients with overt strabismus
  • The corneal epithelium showed obvious fluorescent staining, which was not suitable for patients wearing orthokeratology lenses
  • Patients with dry eye are not suitable for orthokeratology
  • Patients with corneal endothelial cell density less than 2000 cells /mm2
  • Patients who had worn rigid contact lenses (including orthokeratology lenses) within the previous 30 days
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Experimental Group

    Myopic children who need OK lens treatment

    Device: Orthokeratology with 5.0mm back optical zone diameter

  • Active comparator
    Control group

    Myopic children who need OK lens treatment

    Device: Orthokeratology with a 6.2 mm back optical zone diameter

Interventions

  • DeviceOrthokeratology with 5.0mm back optical zone diameter

    The orthokeratology lenses used in this study were Double Reservoir Lenses (DRL) manufactured by Precilens (Creteil, France). The lenses feature a dual reverse-curve design with a back optic zone diameter (BOZD) of 5.0 mm.

  • DeviceOrthokeratology with a 6.2 mm back optical zone diameter

    The orthokeratology lenses used were Euclid lenses manufactured by Euclid Systems (Herndon, VA, USA). These lenses feature a four-zone, five-curve design with a back optic zone diameter (BOZD) of 6.2 mm.

06

What researchers measure

Primary outcomes

  1. Changes in axial length

    Axial length was measured with a biometer

    Time frame: The change of baseline and 1years

Other outcomes

  1. Change of visual quality

    The visual quality questionnaire used in this study was adapted from the questionnaire developed by Tilia et al. The questionnaire comprises five categories with a total of nine questions, each accompanied by descriptive text and illustrative images to assist participants in providing their responses. Participants were asked to select the image corresponding to each question, and their responses were converted into numerical scores ranging from 1 to 10, where a score of 1 represents the poorest visual quality.

    Time frame: Follow-up evaluations were conducted at baseline, and at 1 day, 1 week, 1 month, 3 months, 6 months, and 12 months after lens wear. The differences from baseline were calculated for each follow-up period.

  2. Change of wavefront aberrations

    Wavefront aberration data for the eye were obtained using a Hartmann-Shack wavefront sensor (i.Profiler plus, Carl Zeiss Co., Aalen, Germany). The data were analyzed using Zernike polynomial decomposition to calculate the root mean square (RMS) values of total higher-order aberrations (HOAs), spherical aberration, coma aberration, trefoil, astigmatism, and fourth-order aberrations.

    Time frame: Follow-up evaluations were conducted at baseline, and at 1 day, 1 week, 1 month, 3 months, 6 months, and 12 months after lens wear. The differences from baseline were calculated for each follow-up period.

  3. Change of contract sensitivity

    Contrast sensitivity was assessed using the OPTEC 6500P contrast sensitivity tester (OPTEC 6500P, Stereo Optical Company, Inc., Chicago, USA) at five spatial frequencies: 1.5, 3, 6, 12, and 18 cycles/degree. The contrast sensitivity scores were expressed in logarithmic units (base 10) following a logarithmic transformation.

    Time frame: Follow-up evaluations were conducted at baseline, and at 1 week, 1 month, 3 months, and 12 months after lens wear. The differences from baseline were calculated for each follow-up period.

07

Study locations

1 site
  • Tianjin Eye Hospital Opotometric Center
    Tianjin, Tianjin Municipality 300020, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06825585
Lead sponsor
Xiaoyan Yang
Responsible party
Xiaoyan Yang (Tianjin Eye Hospital, Tianjin Eye Hospital) — Sponsor-investigator
First posted
Feb 13, 2025
Start date
Jan 1, 2021
Primary completion
Mar 31, 2022
Completion
May 31, 2022
Last update
Feb 13, 2025

Study contacts

Tianjin Eye Hospital
principal investigator · Tianjin Eye Hospital Opotometic Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion